News
02-19-2018, 02:44 AM
Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.
More... (https://www.news-medical.net/news/20180219/Myriads-EndoPredict-offers-better-prediction-of-breast-cancer-recurrence-analysis-shows.aspx)
More... (https://www.news-medical.net/news/20180219/Myriads-EndoPredict-offers-better-prediction-of-breast-cancer-recurrence-analysis-shows.aspx)